Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 5 | 2020 | 10 | 1.520 |
Why?
|
| Gynecology | 3 | 2018 | 10 | 1.030 |
Why?
|
| Medical Oncology | 3 | 2018 | 32 | 1.010 |
Why?
|
| Endometrial Neoplasms | 5 | 2022 | 11 | 1.000 |
Why?
|
| Ovarian Neoplasms | 5 | 2019 | 46 | 0.830 |
Why?
|
| Uterine Neoplasms | 2 | 2012 | 8 | 0.830 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 49 | 0.620 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2016 | 12 | 0.600 |
Why?
|
| Genital Diseases, Female | 1 | 2016 | 10 | 0.590 |
Why?
|
| Registries | 1 | 2018 | 189 | 0.580 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 18 | 0.570 |
Why?
|
| Lung Diseases | 1 | 2016 | 46 | 0.570 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 68 | 0.560 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2016 | 10 | 0.560 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2022 | 89 | 0.490 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2018 | 51 | 0.480 |
Why?
|
| Uterus | 2 | 2021 | 15 | 0.460 |
Why?
|
| Female | 24 | 2022 | 16211 | 0.450 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2012 | 1 | 0.420 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2012 | 2 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 132 | 0.420 |
Why?
|
| Uterine Artery Embolization | 1 | 2011 | 2 | 0.410 |
Why?
|
| Intestinal Fistula | 1 | 2011 | 7 | 0.410 |
Why?
|
| Leiomyoma | 1 | 2011 | 10 | 0.410 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 1 | 0.400 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2011 | 2 | 0.400 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 7 | 0.400 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2010 | 1 | 0.370 |
Why?
|
| DNA Methylation | 1 | 2011 | 124 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 290 | 0.360 |
Why?
|
| Postoperative Complications | 1 | 2016 | 957 | 0.360 |
Why?
|
| Humans | 24 | 2022 | 29361 | 0.330 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 379 | 0.290 |
Why?
|
| Middle Aged | 11 | 2019 | 9823 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 184 | 0.270 |
Why?
|
| Platinum | 1 | 2022 | 5 | 0.220 |
Why?
|
| Mutation | 2 | 2022 | 383 | 0.220 |
Why?
|
| Paclitaxel | 2 | 2021 | 74 | 0.210 |
Why?
|
| Aged | 8 | 2018 | 9447 | 0.210 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 5 | 0.210 |
Why?
|
| Infertility, Female | 1 | 2021 | 19 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2021 | 35 | 0.200 |
Why?
|
| Adult | 8 | 2018 | 8604 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 4851 | 0.180 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.180 |
Why?
|
| Phthalazines | 1 | 2019 | 8 | 0.180 |
Why?
|
| Neoplasms | 1 | 2022 | 247 | 0.170 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2018 | 1 | 0.170 |
Why?
|
| Hydrazines | 1 | 2018 | 5 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 5 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 19 | 0.170 |
Why?
|
| Dextrocardia | 1 | 2018 | 3 | 0.170 |
Why?
|
| Piperazines | 1 | 2019 | 90 | 0.160 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 13 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 340 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2018 | 67 | 0.150 |
Why?
|
| Certification | 1 | 2018 | 49 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2018 | 209 | 0.150 |
Why?
|
| Hysterectomy | 2 | 2021 | 19 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 218 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2016 | 3273 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2016 | 64 | 0.150 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 3 | 0.150 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 32 | 0.140 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1184 | 0.140 |
Why?
|
| DNA Mismatch Repair | 2 | 2016 | 6 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3476 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2018 | 158 | 0.140 |
Why?
|
| Illinois | 1 | 2016 | 241 | 0.140 |
Why?
|
| Survival Rate | 2 | 2021 | 349 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 79 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2016 | 145 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 333 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 175 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 178 | 0.130 |
Why?
|
| Incidence | 1 | 2016 | 756 | 0.120 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.120 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 2 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 22 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 56 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2013 | 146 | 0.110 |
Why?
|
| Pedigree | 1 | 2012 | 77 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2022 | 27 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 391 | 0.100 |
Why?
|
| Sirolimus | 2 | 2022 | 15 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2011 | 38 | 0.100 |
Why?
|
| Vagina | 1 | 2011 | 46 | 0.100 |
Why?
|
| Azacitidine | 1 | 2011 | 10 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2011 | 33 | 0.100 |
Why?
|
| United States | 1 | 2018 | 2332 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 80 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 145 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 100 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 145 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 75 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 53 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 265 | 0.090 |
Why?
|
| Morbidity | 1 | 2010 | 63 | 0.090 |
Why?
|
| Risk Factors | 1 | 2016 | 2446 | 0.090 |
Why?
|
| Electronic Health Records | 2 | 2020 | 66 | 0.090 |
Why?
|
| Patient Care | 1 | 2010 | 34 | 0.090 |
Why?
|
| Tomography, X-Ray | 1 | 2009 | 1 | 0.090 |
Why?
|
| Prognosis | 1 | 2012 | 840 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1829 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 88 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2010 | 678 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2012 | 1812 | 0.070 |
Why?
|
| Vulvar Diseases | 1 | 2005 | 3 | 0.070 |
Why?
|
| Granuloma | 1 | 2005 | 13 | 0.070 |
Why?
|
| Quality of Life | 2 | 2020 | 664 | 0.070 |
Why?
|
| Young Adult | 1 | 2011 | 1935 | 0.060 |
Why?
|
| Medical Futility | 1 | 2022 | 3 | 0.050 |
Why?
|
| Strategic Planning | 1 | 2021 | 5 | 0.050 |
Why?
|
| Epothilones | 1 | 2021 | 2 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 25 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 16 | 0.050 |
Why?
|
| Carboplatin | 1 | 2021 | 49 | 0.050 |
Why?
|
| Folic Acid | 1 | 2019 | 16 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 340 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 40 | 0.040 |
Why?
|
| Heart | 1 | 2018 | 91 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 2 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 2 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 6 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 5 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 7 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 6 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2016 | 59 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 76 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 65 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 89 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 255 | 0.030 |
Why?
|
| Male | 1 | 2011 | 15637 | 0.030 |
Why?
|
| Metaplasia | 1 | 2013 | 11 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 45 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 357 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2013 | 394 | 0.030 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 2 | 0.030 |
Why?
|
| Colposcopy | 1 | 2011 | 3 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 2011 | 17 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 521 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 441 | 0.020 |
Why?
|
| Dyspareunia | 1 | 2005 | 7 | 0.020 |
Why?
|
| Analgesics | 1 | 2005 | 108 | 0.020 |
Why?
|
| Recurrence | 1 | 2005 | 350 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 495 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2005 | 462 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 295 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 300 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 1939 | 0.010 |
Why?
|